https://orcid.org/0000-0002-8493-3785
References
- Yan HM, Xia MF, Wang Y, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One. 2015;10(8):1–16.
- Peng K, Wang S, Gao L, et al. A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease. Medicine (Baltimore). 2021;100(26):1–8.
- Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344.
- Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy. J Clin Med. 2019;9(1):15.
- Kawaguchi K, Sakai Y, Terashima T, et al. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Medicine (Baltimore). 2021;100(31):1–7.
- Xu Y, Guo W, Zhang C, et al. Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. Front Pharmacol. 2020;11:601.
- Yuan X, Wang J, Tang X, et al. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med. 2015;13(24):1–11.
- Zhao T, Mao L, Yu Z, et al. Therapeutic potential of bicyclol in liver diseases: lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. Int Immunopharmacol. 2021;91. DOI:https://doi.org/10.1016/j.intimp.2020.107308
- Li H, Xu Q, Xu C, et al. Bicyclol regulates hepatic gluconeogenesis in rats with type 2 diabetes and non-alcoholic fatty liver disease by inhibiting inflammation. Front Pharmacol. 2021;12:1–11.
- Wang Y, Lai R, Zong P, et al. Bicyclol for the treatment of drug-induced liver injury: a propensity score matching analysis using a nationwide inpatient database. J Int Med Res. 2021;49(4):3000605211005945.
- Tan XS, Ma JY, Feng R, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One. 2013;8(10):e77969.
- Chen P, Li Y, Xiao L. Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. Exp Ther Med. 2021;22(4):1109.
- National Workshop on Fatty Liver and Alcoholic Liver Disease. Chinese society of hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update. Chin J Hepatol 2018; 26(3):195–203. [Article in Chinese].
- Han Y, Shi JP, Ma AL, et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig. 2014;34(1):1–7.
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.
- Xie W, Shi G, Zhang H, et al. A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by Adefovir dipivoxil or Adefovir dipivoxil plus bicyclol. Hepatol Int. 2011;6(2):441–448.
- Li H, Liu NH, Peng ZG. Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis. BMJ Open. 2020;10(12):e039700.
- Katsagoni CN, Papatheodoridis GV, Ioannidou P, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr. 2018;120(2):164–175.
- Scapaticci S, D’Adamo E, Mohn A, et al. Non-alcoholic fatty liver disease in obese youth with insulin resistance and type 2 diabetes. Front Endocrinol. 2021;12:639548.
- Farrell GC, Wong VW, Chitturi S. NAFLD in Asia–as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10(5):307–318.
- Chalasani N, Younossi Z , Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Clin Liver Dis. 2018;11(4):81.